ncepod systemic anti-cancer therapy report jcco ….pptVIP

NCEPOD Systemic Anti-Cancer Therapy ReportJCCO Response Dr Jane Barrett Dr Alison Jones JCCO Joint Collegiate Council for Oncology Representatives from RCR RCP RCPath (Haematology) RCGP Trainees National Cancer Director Patients Palliative care Cover UK (cf NCEPOD not Scotland) Representative on NCEPOD JCCO Objectives Implementation of good standards Advice on the Provision of Cancer Services Co-ordination of Training between Clinical and Medical Oncology Advice to Doh on manpower NCEPOD Systemic Anti-Cancer Therapy Report 475,050 SACT in 2006 Study period June July 2006 659/1044 questionnaires returned 86% palliative intent NCEPOD Systemic Anti-Cancer Therapy Report 98% patients are alive at 30 days 2% patients die within 30 days of SACT 35% received care judged as good 57% received satisfactory care 8% received less than satisfactory care NCEPOD Systemic Anti-Cancer Therapy Report Some consent forms inadequate or absent Prescription charts poor quality 19% decisions to treat inappropriate Neutropenic sepsis admissions cause problems 27% deaths were hastened by SACT End of life care could be improved for some What should JCCO do in response to “For Better or For Worse”? What has JCCO already achieved? Issues from this report for the JCCO Plans for the future What JCCO has done since 2006 Document published E-learning “Cancer Doctors of the future” review Guidelines for practice Patient engagement Joint audit February 2007 Cancer network guidelines Service Specification Patient Centred Care E-learning Core curriculum development E-learning for Health bid with Doh accepted 2007; (￡1 M) Interactive learning for first 2 years of taught curriculum Involvement of all medical and clinical oncologists “Cancer Doctors of the future” review Cancer Doctors of the future event Nov 2007 Workforce census Build on this collaborative working Next meeting Spring 2009 JCCO audit Systemic waiting times for chemotherapy Reasons for selecting topic Increasing waitin